BR112022005345A2 - Composições imunogênicas - Google Patents
Composições imunogênicasInfo
- Publication number
- BR112022005345A2 BR112022005345A2 BR112022005345A BR112022005345A BR112022005345A2 BR 112022005345 A2 BR112022005345 A2 BR 112022005345A2 BR 112022005345 A BR112022005345 A BR 112022005345A BR 112022005345 A BR112022005345 A BR 112022005345A BR 112022005345 A2 BR112022005345 A2 BR 112022005345A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic compositions
- field
- vaccines
- bacteria
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSIÇÕES IMUNOGÊNICAS. A presente invenção refere-se a cepas bacterianas, particularmente para uso no campo de vacinas, em particular no campo da prevenção ou tratamento de infecções causadas por bactérias do gênero Bordetella.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19200878.7A EP3799884A1 (en) | 2019-10-01 | 2019-10-01 | Immunogenic compositions |
PCT/EP2020/077416 WO2021064050A1 (en) | 2019-10-01 | 2020-09-30 | Immunogenic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022005345A2 true BR112022005345A2 (pt) | 2023-04-25 |
Family
ID=68136165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022005345A BR112022005345A2 (pt) | 2019-10-01 | 2020-09-30 | Composições imunogênicas |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220339277A1 (pt) |
EP (2) | EP3799884A1 (pt) |
JP (1) | JP2022550560A (pt) |
KR (1) | KR20220070279A (pt) |
CN (1) | CN114502193A (pt) |
AU (1) | AU2020358775A1 (pt) |
BR (1) | BR112022005345A2 (pt) |
CA (1) | CA3156017A1 (pt) |
IL (1) | IL291559A (pt) |
MX (1) | MX2022003871A (pt) |
WO (1) | WO2021064050A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202211033D0 (en) | 2022-07-28 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Purification process |
CN117417419B (zh) * | 2023-01-10 | 2024-04-19 | 康希诺生物股份公司 | 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR5388E (fr) | 1905-06-08 | 1906-03-27 | Jean Eugene Gabillon | Radiateur à grand pouvoir refroidissant pour automobiles |
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
ES2078258T3 (es) | 1989-04-28 | 1995-12-16 | Sclavo Spa | Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas. |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
ES2210262T3 (es) | 1993-09-22 | 2004-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas. |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP1167377B2 (en) | 1994-07-15 | 2012-08-08 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
EP0831901B2 (en) | 1995-06-07 | 2005-12-07 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein |
US6558677B2 (en) | 1996-10-15 | 2003-05-06 | Wendell D. Zollinger | Vaccine against gram negative bacteria |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
ES2301181T3 (es) * | 1997-08-21 | 2008-06-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas. |
KR100704826B1 (ko) | 1998-08-19 | 2007-04-09 | 박스터 헬쓰케어 에스.에이. | N-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트 |
KR100865706B1 (ko) | 2000-09-26 | 2008-10-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법 |
WO2002077183A2 (en) * | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
JPWO2003050782A1 (ja) | 2001-12-12 | 2005-04-21 | 株式会社法学館 | 演習問題出題システム |
GB0202901D0 (en) | 2002-02-07 | 2002-03-27 | Glaxosmithkline Biolog Sa | Novel vaccine |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
GB0424092D0 (en) * | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
EA016417B1 (ru) | 2006-09-07 | 2012-04-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ получения вакцины |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
CA2865248A1 (en) | 2012-02-28 | 2013-09-06 | The Board Of Regents Of The University Of Texas System | Synthetic lipid biology for combinatorial engineering of endotoxin |
PL404247A1 (pl) * | 2013-06-07 | 2014-12-08 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis |
US10420833B2 (en) | 2014-05-19 | 2019-09-24 | Board Of Regents, The University Of Texas System | Combinatorial platform for the display of surface adjuvants and antigens |
MX2019001167A (es) | 2016-07-28 | 2019-09-16 | Max Planck Gesellschaft | Derivados sinteticos estables de poliribosilribitolfosfato resistentes a la hidrolisis como vacunas contra haemophilus influenzae tipo b. |
JP7311227B2 (ja) | 2017-03-13 | 2023-07-19 | イントラヴァック ビー.ブイ. | 低下した反応源性を有するlpsを含むボルデテラワクチン |
RU2020122024A (ru) * | 2017-12-04 | 2022-01-10 | Де Стат Дер Недерланден, Верт. Дор Де Министер Ван Ввс, Министери Ван Волксгезондхейд, Велзейн Ен Спорт | Улучшенный способ получения везикул внешней мембраны |
-
2019
- 2019-10-01 EP EP19200878.7A patent/EP3799884A1/en not_active Ceased
-
2020
- 2020-09-30 US US17/763,354 patent/US20220339277A1/en active Pending
- 2020-09-30 WO PCT/EP2020/077416 patent/WO2021064050A1/en unknown
- 2020-09-30 AU AU2020358775A patent/AU2020358775A1/en active Pending
- 2020-09-30 CN CN202080069731.5A patent/CN114502193A/zh active Pending
- 2020-09-30 MX MX2022003871A patent/MX2022003871A/es unknown
- 2020-09-30 KR KR1020227014156A patent/KR20220070279A/ko unknown
- 2020-09-30 BR BR112022005345A patent/BR112022005345A2/pt unknown
- 2020-09-30 EP EP20776213.9A patent/EP4038090A1/en active Pending
- 2020-09-30 CA CA3156017A patent/CA3156017A1/en active Pending
- 2020-09-30 JP JP2022520197A patent/JP2022550560A/ja active Pending
-
2022
- 2022-03-21 IL IL291559A patent/IL291559A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4038090A1 (en) | 2022-08-10 |
US20220339277A1 (en) | 2022-10-27 |
AU2020358775A1 (en) | 2022-04-14 |
CA3156017A1 (en) | 2021-04-08 |
WO2021064050A1 (en) | 2021-04-08 |
EP3799884A1 (en) | 2021-04-07 |
KR20220070279A (ko) | 2022-05-30 |
CN114502193A (zh) | 2022-05-13 |
MX2022003871A (es) | 2022-06-02 |
IL291559A (en) | 2022-05-01 |
JP2022550560A (ja) | 2022-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018077266A2 (pt) | composições compreendendo cepas bacterianas | |
WO2018115527A3 (en) | Mers coronavirus vaccine | |
MX2022006525A (es) | Activo de polipeptidos de lisina contra bacterias gram-negativas. | |
EP4282489A3 (en) | Treatment of clostridium difficile infection | |
PH12016501577A1 (en) | Monobactam organic compounds for the treatment of bacterial infections | |
BR112018068593A2 (pt) | composições tópicas não aquosas que compreendem uma salicilanilida halogenada | |
MX2018001075A (es) | Agentes terapeuticos y profilacticos antibacterianos. | |
MD3743086T2 (ro) | Compoziții cuprizând tulpini bacteriene | |
MX2019007613A (es) | Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos. | |
BRPI0807487A8 (pt) | Uso de antagonistas de il-23 para o tratamento de infecção | |
CL2011002639A1 (es) | Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis. | |
PH12019500360A1 (en) | Antibiotic compounds | |
MX2021002719A (es) | Cannabinoides para el tratamiento de infecciones grampositivas incluidas cepas bacterianas resistentes a antibióticos. | |
UY31437A1 (es) | Vacuna de mycoplasma bovis y métodos de uso de la misma | |
PH12016501988A1 (en) | Antibacterial compounds | |
BR112017014670A2 (pt) | derivado de polimixina e usos do mesmo | |
BR112022005345A2 (pt) | Composições imunogênicas | |
ZA202002093B (en) | Antibacterial compounds | |
PH12018500358A1 (en) | Compounds for use in an antibacterial applications | |
EP4241851A3 (en) | Immunogenic compositions | |
MX2018011095A (es) | Compuestos de carbapenem. | |
NZ737820A (en) | Mannose derivatives for treating bacterial infections | |
AU2018257122A1 (en) | Pharmaceutical composition comprising attenuated streptococcus pneumoniae strains and use thereof | |
BR112019002023A2 (pt) | prevenção ou tratamento de infecções antifúngicas vetorizado por bactérias probióticas | |
MX2019006086A (es) | Uso de una composicion bacteriana para tratar infecciones en las patas de ungulados. |